-
公开(公告)号:US10143683B2
公开(公告)日:2018-12-04
申请号:US15791093
申请日:2017-10-23
IPC分类号: A61K9/14 , A61K9/48 , A61K38/00 , A61K31/497 , A61K31/505 , B01F3/00 , A61K31/44 , A61K31/506 , A61K31/517 , A61K9/51 , A61K31/437 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K47/32 , A61K47/38 , A61K31/444 , A61K9/16 , A61K9/00
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
公开(公告)号:US20160250153A1
公开(公告)日:2016-09-01
申请号:US15153807
申请日:2016-05-13
IPC分类号: A61K9/51 , A61K31/517 , A61K31/437 , A61K31/44 , A61K31/444 , A61K31/506 , A61K31/5377
CPC分类号: A61K31/44 , A61K9/0053 , A61K9/14 , A61K9/1641 , A61K9/1652 , A61K9/5138 , A61K9/5146 , A61K9/5161 , A61K9/5192 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K47/32 , A61K47/38
摘要: The present invention relates to the field of methods for providing components of pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to methods for providing stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions.
摘要翻译: 本发明涉及用于提供包含难溶于水的药物的药物组合物的组分的方法领域。 特别地,本发明涉及提供稳定的无定形杂化纳米颗粒的方法,其包含至少一种可用于药物组合物的蛋白激酶抑制剂和至少一种聚合物稳定和基质形成组分。
-
公开(公告)号:US10561644B2
公开(公告)日:2020-02-18
申请号:US16404004
申请日:2019-05-06
IPC分类号: A61K9/14 , A61K9/48 , A61K38/00 , A61K31/497 , A61K31/505 , B01F3/00 , A61K31/44 , A61K31/517 , A61K9/51 , A61K31/437 , A61K31/506 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K47/32 , A61K47/38 , A61K31/444 , A61K9/16 , A61K9/00
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
公开(公告)号:US20190255029A1
公开(公告)日:2019-08-22
申请号:US16404004
申请日:2019-05-06
IPC分类号: A61K31/44 , A61K31/517 , A61K9/14 , A61K31/437 , A61K9/16 , A61K9/00 , A61K31/444 , A61K31/5377 , A61K31/4439 , A61K31/4545 , A61K31/506 , A61K9/51 , A61K47/38 , A61K47/32
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
公开(公告)号:US20190060294A1
公开(公告)日:2019-02-28
申请号:US16176101
申请日:2018-10-31
IPC分类号: A61K31/44 , A61K31/5377 , A61K9/14 , A61K31/4545 , A61K31/517 , A61K9/51 , A61K31/437 , A61K9/16 , A61K9/00 , A61K31/444 , A61K31/506 , A61K47/38 , A61K47/32 , A61K31/4439
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
公开(公告)号:US09833443B2
公开(公告)日:2017-12-05
申请号:US15423183
申请日:2017-02-02
IPC分类号: A61K9/14 , A61K9/48 , A61K38/00 , A61K31/497 , A61K31/505 , B01F3/00 , A61K31/44 , A61K31/506 , A61K31/517 , A61K9/51 , A61K31/437 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K47/32 , A61K47/38 , A61K31/444 , A61K9/16 , A61K9/00
CPC分类号: A61K31/44 , A61K9/0053 , A61K9/14 , A61K9/1641 , A61K9/1652 , A61K9/5138 , A61K9/5146 , A61K9/5161 , A61K9/5192 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K47/32 , A61K47/38
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
公开(公告)号:US20160361313A1
公开(公告)日:2016-12-15
申请号:US15248107
申请日:2016-08-26
IPC分类号: A61K31/506 , A61K31/517 , A61K31/437 , A61K31/44 , A61K31/4545 , A61K31/4439 , A61K9/16 , A61K31/5377
CPC分类号: A61K31/44 , A61K9/0053 , A61K9/14 , A61K9/1641 , A61K9/1652 , A61K9/5138 , A61K9/5146 , A61K9/5161 , A61K9/5192 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K47/32 , A61K47/38
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
摘要翻译: 本发明涉及用于提供包含难溶于水的药物的药物组合物的方法领域。 特别地,本发明涉及包含稳定的无定形杂合纳米颗粒的组合物,其包含至少一种蛋白激酶抑制剂和至少一种可用于药物组合物和治疗中的聚合物稳定和基质形成组分。
-
公开(公告)号:US20140044819A1
公开(公告)日:2014-02-13
申请号:US14051107
申请日:2013-10-10
发明人: Mustafa Demirbüker
IPC分类号: B01J2/06
CPC分类号: B01J2/06 , A61K9/1688 , B01J2/04 , B01J4/002 , B01J19/26
摘要: A production arrangement for producing a batch of particles having predetermined sizes and/or morphology comprising at least a) two or more spray nozzles, each having a fluid transport conduit, a solution transport conduit, and a mixing arrangement for mixing a fluid and a solution with each other downstream of the fluid transport conduit, and a spray outlet, b) one or more particle collecting chambers, each comprising the spray outlet of at least one of the spray nozzles and a function for separating and collecting particles produced in the spray nozzle from the solution-fluid mixture, and c) a transport conduit external to the spray nozzles for transferring fluid to the fluid transport conduits of the spray nozzles, wherein the spray nozzles are identical and adapted to be run simultaneously with at least two of them being placed in a same particle collecting chamber and/or in different particle collecting chambers.
摘要翻译: 一种用于生产一批具有预定尺寸和/或形态的颗粒的生产装置,包括至少一个)两个或更多个喷嘴,每个喷嘴具有流体输送导管,溶液输送导管和用于混合流体和溶液的混合装置 彼此在流体输送导管的下游和喷雾出口,b)一个或多个颗粒收集室,每个颗粒收集室包括至少一个喷嘴的喷雾出口和用于分离和收集在喷嘴中产生的颗粒的功能 并且c)在所述喷嘴外部的输送管道,用于将流体传送到所述喷嘴的流体输送管道,其中所述喷嘴是相同的并适于同时运行,其中至少两个喷嘴是 放置在相同的颗粒收集室和/或不同的颗粒收集室中。
-
公开(公告)号:US10314830B2
公开(公告)日:2019-06-11
申请号:US16176101
申请日:2018-10-31
IPC分类号: A61K9/14 , A61K9/48 , A61K38/00 , A61K31/497 , A61K31/505 , B01F3/00 , A61K31/44 , A61K31/5377 , A61K31/4439 , A61K31/4545 , A61K31/517 , A61K9/51 , A61K31/437 , A61K9/16 , A61K9/00 , A61K31/444 , A61K31/506 , A61K47/38 , A61K47/32
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
公开(公告)号:US20190076413A1
公开(公告)日:2019-03-14
申请号:US16173466
申请日:2018-10-29
IPC分类号: A61K31/44 , A61K31/5377 , A61K9/14 , A61K31/4545 , A61K31/517 , A61K9/51 , A61K31/437 , A61K9/16 , A61K9/00 , A61K31/444 , A61K31/506 , A61K47/38 , A61K47/32 , A61K31/4439
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
-
-
-
-
-
-
-
-